Landos Biopharma Inc

NASDAQ:LABP   1:17:41 PM EDT
11.06
-0.63 (-5.39%)
Products

Landos Biopharma And LianBio Collaborate To Develop And Commercialize Omilancor And NX-13 In Greater China And Select Asian Markets

Published: 05/17/2021 11:22 GMT
Landos Biopharma Inc (LABP) - Landos Biopharma and Lianbio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and Nx-13 in Greater China and Select Asian Markets.
Landos Biopharma Inc - Lianbio Will Receive Exclusive Rights to Develop and Commercialize Omilancor and Nx-13 in Greater China, Other Countries.
Landos Biopharma - Landos Will Receive Upfront Cash Payment of $18 Million & Eligible to Receive Milestone Payments of Up to $200 Million.
Landos Biopharma Inc - Lianbio Will Fund Development and Commercialization Expenses in Collaboration Territory.
Landos Biopharma Inc - Landos Will Continue to Fund All Development and Commercialization Expenses in All Other Geographies.